This week’s clinical AI milestones reveal a structural fault line: the capability to transform global healthcare now exists, but the market will not deploy it where the need is greatest.
Nobel laureate David Baker’s team develops AI breakthrough for targeting ‘undruggable’ intrinsically disordered proteins, opening paths to treat cancers, neurodegenerative disorders, and metabolic conditions. Despite technological promise, implementation raises critical questions about AI diagnostic reliability and healthcare trust.
AI is revolutionizing drug discovery by accurately predicting protein structures, accelerating target identification, and designing novel molecules, dramatically reducing development timelines from years to months while addressing untreatable conditions.
